Cannabinoids suppress inflammatory and neuropathic pain by targeting 3 glycine receptors

Laboratory for Integrative Neuroscience, National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD 20892, USA.
Journal of Experimental Medicine (Impact Factor: 12.52). 05/2012; 209(6):1121-34. DOI: 10.1084/jem.20120242
Source: PubMed


Certain types of nonpsychoactive cannabinoids can potentiate glycine receptors (GlyRs), an important target for nociceptive regulation at the spinal level. However, little is known about the potential and mechanism of glycinergic cannabinoids for chronic pain treatment. We report that systemic and intrathecal administration of cannabidiol (CBD), a major nonpsychoactive component of marijuana, and its modified derivatives significantly suppress chronic inflammatory and neuropathic pain without causing apparent analgesic tolerance in rodents. The cannabinoids significantly potentiate glycine currents in dorsal horn neurons in rat spinal cord slices. The analgesic potency of 11 structurally similar cannabinoids is positively correlated with cannabinoid potentiation of the α3 GlyRs. In contrast, the cannabinoid analgesia is neither correlated with their binding affinity for CB1 and CB2 receptors nor with their psychoactive side effects. NMR analysis reveals a direct interaction between CBD and S296 in the third transmembrane domain of purified α3 GlyR. The cannabinoid-induced analgesic effect is absent in mice lacking the α3 GlyRs. Our findings suggest that the α3 GlyRs mediate glycinergic cannabinoid-induced suppression of chronic pain. These cannabinoids may represent a novel class of therapeutic agents for the treatment of chronic pain and other diseases involving GlyR dysfunction.

Download full-text


Available from: Yun Guan, Jan 16, 2014
  • Source
    • "The development of α3-selective glycine receptor modulators may be guided by observations that some cannabinoids can positively or negative modulate glycine receptor activity in a subunit-selective manner [107]. Indeed, recent work demonstrated that the non-psychoactive cannabinoid cannabidiol potentiated the activity of glycine receptors and induced antihyperalgesia in an α3 subunit-dependent manner [104]. Additionally, removing glycine receptor inhibition by blocking the production of PGE2 can also increase glycine receptor function to inhibit hyperalgesia [43]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Neuronal inhibition in nociceptive relay of the spinal cord dorsal horn is essential for the proper processing of nociceptive information. In the spinal cord dorsal horn, the activity of synaptic and extrasynaptic GABAA and glycine receptors generates rapid, Cl(-)-dependent neuronal inhibition. A loss of this ionotropic inhibition, particularly through the collapse of the inhibitory Cl(-) gradient, is a key mechanism by which pathological pain conditions can develop. This review summarizes the roles of ionotropic inhibition in the regulation of nociception, and explores recent evidence that the enhancement of GABAA or glycine receptor activity or inhibitory drive can reverse pathological pain.
    Neuroscience Letters 09/2013; 557. DOI:10.1016/j.neulet.2013.09.047 · 2.03 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Strychnine-sensitive glycine receptors (GlyRs) mediate synaptic inhibition in spinal cord, brainstem and other regions of the mammalian central nervous system. This review summarizes our current view of the structure, ligand binding sites and chloride channel of these receptors and discusses recently emerging functions of distinct GlyR isoforms. GlyRs regulate not only the excitability of motor and afferent sensory neurons including pain fibers, but are also involved in the processing of visual and auditory signals. Hence, GlyRs constitute promising targets for the development of therapeutically useful compounds.
    Journal of Biological Chemistry 10/2012; 287(48). DOI:10.1074/jbc.R112.408229 · 4.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cannabidiol (CBD) is a plant-derived cannabinoid that has been predominantly characterized as anti-inflammatory. However, it is clear that immune effects of cannabinoids can vary with cannabinoid concentration, or type or magnitude of immune stimulus. The present studies demonstrate that oral administration of CBD enhanced lipopolysaccharide (LPS)-induced pulmonary inflammation in C57BL/6 mice. The enhanced inflammatory cell infiltrate as observed in bronchoalveolar lavage fluid (BALF) was comprised mainly of neutrophils, with some monocytes. Concomitantly, CBD enhanced pro-inflammatory cytokine mRNA production, including tumor necrosis factor-α (Tnfa), interleukins (IL)-5 and -23 (Il6, Il23), and granulocyte colony stimulating factor (Gcsf). These results demonstrate that the CBD-mediated enhancement of LPS-induced pulmonary inflammation is mediated at the level of transcription of a variety of pro-inflammatory genes. The significance of these studies is that CBD is part of a therapeutic currently in use for spasticity and pain in multiple sclerosis patients, and therefore it is important to further understand mechanisms by which CBD alters immune function.
    Journal of Immunotoxicology 11/2012; 10(3). DOI:10.3109/1547691X.2012.741628 · 2.05 Impact Factor
Show more